Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain

Commentary
Video

The head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed research from the center presented at ASGCT 2024.

“Gene therapy is enormously promising for a lot of neurological indications. For many of them, the genetics are well known, you know what you'd want to change, if you could, but now [to figure out] delivery. How do you get those genes into that cell, make that edit, make that correction, that’s what really hangs over the field. And if those technologies can be unlocked, there are many diseases and thousands of patients that could potentially be treated.”

A number of researchers from Mass General Brigham (MGB) presented work at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland. A good amount of this work centered on new technologies and new methods aiming to improve gene and cell therapy and its delivery to different tissues, particularly the brain.

CGTLive® spoke with Nathan Yozwiak, PhD, head of research, Cell and Gene Therapy Institute, MGB, to learn more about research presented at the ASGCT meeting coming out of the center. He highlighted 2 presentations, one given by Casey Maguire, PhD, on encapsulated adeno-associated virus (AAV) vectors and another given by Nick Todd, PhD, on ultrasound-mediated delivery of AAV. Both presentations have potential in achieving gene therapy delivery past the blood-brain barrier for treating neurologic indications.

REFERENCES
1. Cheng M, de la Cruz D, Ng C, et al. New Biological Insights into Extracellular Vesicle Associated AAV Help Improve Vector Yield and Provides Rational for Intraluminal AAV Packing. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract 221.
2. Owusu-Yaw B, Zhang Y, Garrett L, et al. Focused Ultrasound-Mediated Delivery of AAV9-Based Gene Therapy in Aged Huntington’s Disease Mice. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract 623

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.